|
Volumn 60, Issue 12, 2011, Pages 736-740
|
CDC update on gonorrhea: Expand treatment to limit resistance
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZITHROMYCIN;
CEFIXIME;
CEFOTAXIME;
CEFOXITIN;
CEFTIZOXIME;
CEFTRIAXONE;
CEPHALOSPORIN DERIVATIVE;
DOXYCYCLINE;
PENICILLIN G;
PROBENECID;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
TETRACYCLINE;
ANTIBIOTIC RESISTANCE;
ANTIBIOTIC SENSITIVITY;
BACTERIUM CULTURE;
CHLAMYDIA TRACHOMATIS;
CHLAMYDIASIS;
CLINICAL PROTOCOL;
DRUG EFFICACY;
DRUG TREATMENT FAILURE;
FOLLOW UP;
GONORRHEA;
HIGH RISK POPULATION;
HUMAN;
MANDATORY REPORTING;
MIXED INFECTION;
PRACTICE GUIDELINE;
PREVALENCE;
PUBLIC HEALTH SERVICE;
RISK FACTOR;
SCREENING TEST;
SHORT SURVEY;
SINGLE DRUG DOSE;
ANTI-BACTERIAL AGENTS;
AZITHROMYCIN;
CEFTRIAXONE;
CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.);
CHLAMYDIA INFECTIONS;
CHLAMYDIA TRACHOMATIS;
DRUG RESISTANCE, BACTERIAL;
DRUG THERAPY, COMBINATION;
FOLLOW-UP STUDIES;
GONORRHEA;
HUMANS;
MICROBIAL SENSITIVITY TESTS;
NEISSERIA GONORRHOEAE;
PRACTICE GUIDELINES AS TOPIC;
PREVALENCE;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 84856818499
PISSN: 00943509
EISSN: 15337294
Source Type: Journal
DOI: None Document Type: Short Survey |
Times cited : (6)
|
References (4)
|